World Expert on Liver Disease Joins the Scientific Advisory Board of Medgenics
07 December 2009 - 9:44PM
Business Wire
Medgenics (AIM: MEDG and MEDU), the biopharmaceutical company
that creates implantable therapeutic protein producing Biopumps,
announced today that Dr. Bruce R. Bacon was appointed to the
Scientific Advisory Board of the Company.
Dr. Bacon is a former President of the American Association for
the Study of Liver Diseases (AASLD) and a recognised World expert
on Hepatitis. Dr. Bacon is the James F. King, MD Endowed Chair in
Gastroenterology, Professor of Internal Medicine, and Director of
the Division of Gastroenterology and Hepatology at Saint Louis
University School of Medicine in St. Louis, Missouri. The potential
treatment of Hepatitis using the Company’s patented INFRADURE
technology is one of the core projects that the Company is seeking
to commercialise. Medgenics reported consistently promising and
unprecedented results from the safety and efficacy clinical trial
of its EPODURE Biopumps for sustained anaemia treatment from a
single administration, in progress since September 2008. Biopumps
are made from tissue taken by needle biopsy taken from under the
patient’s own skin and processed to become implantable biofactories
to provide the required therapeutic protein for many months. The
INFRADURE technology has been similarly used to create implantable
Biopumps that produce Interferon Alpha for months and will offer a
significant addition to the physician’s Hepatitis armamentarium to
treat this scourge of a disease.
Dr. Eugene Bauer, Chairman of Medgenics commented:“We are
delighted to welcome Dr. Bacon to Medgenics. As one of the world’s
top experts in Hepatitis C, he brings a wealth of experience and
influence to the company. Hepatitis is one of the core areas of
treatment that we are seeking to commercialise. Having an expert of
Dr. Bacon’s calibre is essential as we move into the clinic with
the exciting new approach to treatment that our INFRADURE
technology offers. Our ability to attract leading figures such as
Dr. Bacon demonstrates the growing stature of Medgenics in the
global market for therapeutic protein delivery. I and the rest
of the Board look forward to working with him as we
continue to develop Medgenics.”
Dr. Andrew Pearlman, CEO of Medgenics commented:“The appointment
of Dr. Bacon is another important addition to the senior team at
Medgenics. Coming in the wake of the signing of a hemophilia
development agreement with a major international biopharmaceutical
company, Dr. Bacon’s appointment is a further strong vote
of confidence for Medgenics and our INFRADURE approach to
interferon alpha therapy in the treatment of Hepatitis C.”
About Medgenics:
Medgenics is a clinical-stage biopharmaceutical company
developing its unique tissue-based Biopump platform technology
using the patient’s own skin to provide sustained-action protein
therapy for the treatment of a range of chronic diseases. The
Company currently has three products in development based on this
technology and addressing the indications of:
- Anaemia - using EPODURE, a Biopump producing erythropoietin
(EPO)
- Hepatitis-C - using INFRADURE - a Biopump producing
interferon-alpha (IFN-a)
- Hemophilia - using a Biopump to produce clotting Factor
VIII
The Company's Phase I/II clinical trial using EPODURE to treat
anaemia in patients with chronic kidney disease, has demonstrated
proof of concept of the Biopump. Designed to produce and deliver a
therapeutic dose of EPO steadily for six months or more, EPODURE
Biopumps have already provided effective anaemia treatment in most
of these patients for 6-12 months, even at the low administered
dose.
Medgenics intends to develop its innovative products and bring
them to market via multiple strategic partnerships with major
pharmaceutical and/or medical device companies. In addition to
treatments for Anaemia, Hepatitis-C, Hemophilia, Medgenics plans to
develop and/or out-license a pipeline of future Biopump products
targeting the large and rapidly growing global protein therapy
market, which is forecast to reach US $87 billion by 2010. Other
potential applications of Biopumps producing various proteins
include multiple sclerosis, arthritis, pediatric growth hormone
deficiency, obesity, and diabetes.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024
